Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma

Inclusion criteria

• ✓. Signed written informed consent.
• ✓. Age ≥ 14 years
• ✓. Body surface area ≥ 1.2 m2
• ✓. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• ✓. Histologically confirmed de-differentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma or Ewing sarcoma. Liposarcomas with areas of well-differentiated disease are eligible if there is a biopsy-proven component of dedifferentiated liposarcoma. Pathology is reviewed at Columbia University Medical Center.
• ✓. Disease which is locally advanced and unresectable or metastatic. Disease which may be resected but with an associated level of morbidity deemed unacceptable by the treating clinician is considered eligible.
• ✓. Measurable disease as assessed by RECIST criteria version 1.1.
• ✓. Progression on, or intolerance to, at least one prior systemic regimen for sarcoma (including systemic treatment used in the adjuvant or neoadjuvant settings). For alveolar soft part sarcoma and dedifferentiated liposarcoma, there is no upper limit on the number of prior therapies that may have been received. For Ewing sarcoma and malignant peripheral nerve sheath tumor, patients may have received no more than 3 prior lines of therapy (excluding systemic treatment used in the adjuvant or neoadjuvant settings).